evocatal GmbH Closes New Financing Round
evocatal GmbH has closed € 2 million in growth financing. Thus the industrial biotech company puts itself in a position to continue successfully started projects rigorously to market readiness.
The current financing round is chaired by new investor Roland Oetker, who, together with existing investors High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner, provides € 2 million in growth capital. Founded in 2006, evocatal GmbH has laid the groundwork for an ambitious growth strategy with its seed financing in 2007, and with the now completed follow-on financing the company puts itself in a position to continue successfully started projects rigorously to market readiness.
“In addition to our unique technological position, an excellent team of investors is another strength of evocatal. I am very proud that all existing investors collectively participate in the follow-on financing and thus support the adopted growth strategy“, said a delighted Dr. Thorsten Eggert, founder and CEO of evocatal. “This B round enables us not only to realise the development of new products, but also to create an attractive financial structure for future investors.“, explains Eggert.
“Since its foundation, evocatal has held a strong position in the industrial biotechnology market. We are delighted that the funding will support the team of evocatal in its effort to strengthen this position further and, beyond that, facilitate an expansion into existing and attractive new markets “, comments Ron Winkler (SSFD) on the development at evocatal.
Prof. Dr. Karl-Erich Jaeger, Chairman of the Advisory Board, sees with the entry of the new investor primarily the already existing network of experienced investors and top scientists decisively strengthened. “I am very pleased that with Roland Oetker we have not only gained a renowned new investor, but we are also able to strengthen the advisory board of evocatal with a person who has long-standing experience in the successful financing of biotechnology companies “, states Prof. Jaeger.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Dendrimer technology gets a grip on cell proteins, could improve cancer treatment
Casting off: Leaving autoimmune disease behind thanks to an innovative treatment - Research team makes decisive breakthrough
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01 - Financing secures further clinical trials and the supply of material for the treatment of COVID-19 patients
NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership - Establishing whole genome sequencing centre in Singapore
Gene that influences the ability to remember faces
Estación_de_Fotobiología_Playa_Unión
E. coli bacteria's defense secret revealed
Felicitex Therapeutics and Selvita Initiate Strategic Collaboration to Target Cancer Quiescence
Faecal Pollution: DNA Uncovers Culprit - CSI and forensics can be used to uncover not only serial killers but also the cause of water pollution
Chinese_Mental_Health_Association
Catalent Invests $7.3 Million in Italy - Expands Softgel Encapsulation and Packaging Capabilities in Support of Consumer Health
